Pan-Cancer NGS Panel

This 65-gene NGS panel is designed to profile solid tumor patients for actionable mutations in oncogenes and tumor suppressor genes in clinical studies and clinical trials.

R

Research Service

Introducing OptiSeq™ Pan-Cancer NGS Panel 

Opti-seq™ Pan-cancer 65-gene NGS panel is a targeted NGS panel containing 65 common oncogenes and tumor suppressor genes within 2900 amplicons. These hot mutations include important known mutations, some of which are actionable drug targets. The profiling of solid tumor patients with important mutations provides valuable information in drug therapy clinical studies or trials.

Samples tested: Liquid biopsy (blood/ccfDNA) and FFPE samples (tissue/DNA)

Low DNA input needed: 10ng for detection of somatic mutations (SNP); 100pg for germline mutations

Highly sensitive NGS test allows as low as 1% variant allele frequency (VAF) detection

Sample receipt to clinical report within 10 days. No deep sequencing is required

Comprehensive clinically significant variants, FDA-approved therapies and clinical trials

100% observed uniformity at ≥ 0.2X mean depth and 97% observed uniformity at ≥ 0.5X

Targeted Pan-Cancer 

Many targeted NGS panels target a particular type of cancer. However, when a clinical trial target multiple types of solid tumors, individual cancer NGS panels cannot cover the mutations important for various types of cancers. The Pan-cancer NGS panel contains mutations found in major types of solid tumors. A clinical study or trials that include drug testing on various solid tumors will benefit from this panel.

OptiSeq™ Pan-Cancer Gene Panel (65 Genes)

ABL1AKT1ALKAPCATMBRAFBRCA1
BRCA2CDH1CDKN2ACSF1RCTNNB1DDR2DNMT3A
EGFRERBB2ERBB3ERBB4EZH2FBXW7FGFR1
FGFR2FGFR3FLT3FOXL2GNA11GNAQGNAS
HNF1AHRASIDH1IDH2JAK2JAK3KDR
KITKRASMAP2K1METMLH1MPLMSH6
MTORNF1NF2NOTCH1NPM1NRASPDGFRA
PIK3CAPIK3R1PTCH1PTENPTPN11RB1RET
SMAD4SMARCB1SMOSRCSTK11TERTTP53
TSC1VHL

Resources

GET A QUOTE NOW

X